PubRank

Menno A de Rie

Author PubWeight™ 16.91‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003 2.12
2 Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002 1.22
3 Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004 1.09
4 Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007 1.06
5 Systemic treatment with either cyclosporin A or methotrexate does not influence the T helper 1/T helper 2 balance in psoriatic patients. J Clin Immunol 2004 1.00
6 Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res 2005 0.91
7 Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 2009 0.89
8 The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004 0.89
9 Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res 2004 0.88
10 Etanercept: an overview of dermatologic adverse events. Arch Dermatol 2011 0.87
11 Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol 2002 0.83
12 Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res 2007 0.82
13 Rise in dermal CD11c+ dendritic cells associates with early-stage development of psoriatic lesions. Arch Dermatol Res 2012 0.79
14 Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels. Arch Dermatol 2004 0.77
15 UVB irradiation of normal human skin favors the development of type-2 T-cells in vivo and in primary dermal cell cultures. Photochem Photobiol 2002 0.77
16 A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin. Dermatology 2012 0.76
17 The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: study protocol for a multicenter randomized controlled trial. Trials 2012 0.75
18 Treatment of Basal Cell Carcinoma Using a One-Stop-Shop With Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial. JMIR Res Protoc 2015 0.75
19 A Web-based, educational, quality-of-life intervention for patients with a chronic skin disease: feasibility and acceptance in routine dermatological practice. Acta Derm Venereol 2015 0.75
20 Implementation of Web-based Education for Patients with Chronic Skin Disease. Acta Derm Venereol 2016 0.75
21 Patient-Reported Outcome Measurement in Clinical Dermatological Practice: Relevance and Feasibility of a Web-Based Portal. Dermatology 2015 0.75
22 Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ. Arch Dermatol Res 2002 0.75
23 Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. Exp Dermatol 2010 0.75